Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90B1 | P14625 | 10/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 10/20 | 0.52 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.38 |
| ▸ | MC1R | Q01726 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3978717 | 0.88 | HSP90AA1 (0.46) | HSP90B1HSP90AA1HSP90AB1OPRD1MC1R | |
| SCHEMBL3980102 | 0.85 | HSP90AA1 (0.47) | HSP90B1HSP90AA1HSP90AB1OPRD1MC1R | |
| SCHEMBL3983787 | 0.84 | HSP90AA1 (0.47) | HSP90B1HSP90AA1HSP90AB1OPRD1MC1R | |
| SCHEMBL3984837 | 0.82 | HSP90AA1 (0.45) | HSP90B1HSP90AA1HSP90AB1OPRD1MC1R | |
| SCHEMBL3986911 | 0.82 | HSP90AA1 (0.46) | HSP90B1HSP90AA1HSP90AB1OPRD1MC1R | |
| SCHEMBL3978850 | 0.82 | HSP90AA1 (0.43) | HSP90B1HSP90AA1 | |
| SCHEMBL3983750 | 0.82 | HSP90AA1 (0.43) | HSP90B1HSP90AA1P2RX7OPRK1 | |
| SCHEMBL3982566 | 0.81 | HSP90AA1 (0.45) | HSP90B1HSP90AA1HSP90AB1OPRD1MC1R | |
| SCHEMBL13720182 | 0.81 | HSP90AA1 (0.42) | HSP90B1HSP90AA1OPRD1MC1ROPRK1 | |
| SCHEMBL13720814 | 0.80 | HSP90AA1 (0.46) | HSP90B1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572921-B2 | Substituted benzylimidazoles useful for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-11 | — | — | US | claimed |
| EP-1869012-A1 | SUBSTITUTED BENZYLIMIDAZOLES USEFUL FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-26 | — | — | EP | claimed |
| US-20060252811-A1 | SUBSTITUTED BENZYLIMIDAZOLES USEFUL FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-09 | — | — | US | claimed |
| WO-2006107923-A1 | SUBSTITUTED BENZYLIMIDAZOLES USEFUL FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-12 | — | — | WO | claimed |
| US-7572921-B2 | Substituted benzylimidazoles useful for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-11 | — | — | US | disclosed |
| US-7572921-B2 | Substituted benzylimidazoles useful for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252811-A1 | SUBSTITUTED BENZYLIMIDAZOLES USEFUL FOR THE TREATMENT OF INFLAMMATORY DISEASES | IL4I1, NFKBIA, BRD4 | HSP90B1 557/4885HSP90AA1 675/4885HSP90AB1 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.